Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 25.07M | 24.35M | 15.22M | 1.00M | 14.00M | 749.00K |
Gross Profit | 21.91M | 21.55M | 13.88M | 724.00K | 13.82M | 672.50K |
EBITDA | -61.28M | -65.36M | -60.12M | -109.15M | -2.48M | -24.44M |
Net Income | -61.69M | -65.77M | -57.01M | -110.09M | -3.48M | -23.27M |
Balance Sheet | ||||||
Total Assets | 64.12M | 132.42M | 184.24M | 157.91M | 18.82M | 39.94M |
Cash, Cash Equivalents and Short-Term Investments | 62.61M | 108.84M | 172.56M | 148.99M | 4.46M | 38.52M |
Total Debt | 0.00 | 1.27M | 1.66M | 605.00K | 10.26M | 169.99K |
Total Liabilities | 5.46M | 27.23M | 25.86M | 21.50M | 31.26M | 3.40M |
Stockholders Equity | 58.67M | 105.19M | 158.38M | 136.41M | -12.43M | 36.54M |
Cash Flow | ||||||
Free Cash Flow | -61.03M | -63.63M | -50.08M | -22.47M | -12.70M | -24.09M |
Operating Cash Flow | -61.20M | -59.66M | -49.64M | -22.42M | -12.70M | -23.85M |
Investing Cash Flow | 26.44M | 83.21M | -132.89M | 25.15M | -19.02K | -236.95K |
Financing Cash Flow | 157.00K | 326.00K | 72.62M | 141.80M | 1.19M | 8.07M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
57 Neutral | $50.63M | ― | -65.95% | ― | 7.80% | 3.12% | |
52 Neutral | $7.45B | 0.27 | -61.87% | 2.30% | 16.62% | 1.04% | |
52 Neutral | $82.06M | ― | -78.93% | ― | -70.15% | ― | |
50 Neutral | $3.37B | ― | -106.71% | ― | ― | -22.34% | |
48 Neutral | $496.18M | ― | -37.13% | ― | -38.14% | 29.69% | |
41 Neutral | $14.39M | ― | -105.79% | ― | -82.54% | -12.53% | |
27 Underperform | $145.74M | ― | -102.48% | ― | ― | -7.78% |
Aadi Bioscience has entered into a Stock Purchase Agreement with KAKEN Pharmaceutical, selling its subsidiary, including the FYARRO business, for $100 million, which will fund operations into late 2028. Additionally, Aadi has secured an exclusive license for three novel ADC assets from WuXi Biologics and announced a $100 million PIPE financing to support the development of these assets, indicating a strategic shift towards leveraging advanced ADC technologies to address unmet cancer therapeutic needs.